Both Sad and Eklund, L. K., 3338
El-Rifai, W., 3230
Farmer, A. A., 3168
Feron, R., 3301
Ferrero, E., 3211
Ferrero, M. E., 3211
Fitton, J. E., 3287
Flynn, A. A., 3293
Fong, Y., 3225
Fontham, E. T. H., 3238
Friedman, A. D., 3250
Fujii, A., 3196
Fujimoto, N., 3196
Gallez, B., 3344
Galloway, S. M., 3257
Giroldi, L. A., 3234
Goda, F., 3344
Gohji, K., 3196
Govers, M. J. A. P., 3270
Graeber, L. A., 3315
Gregel, C. M., 3244
Gront, T., 3350
Gubba, S., 3180
Guinebretiere, J.-M., 3216
Hanlon, M. H., 3301
Hata, J.-i., 3320
Helling, F., 3315
Hemminki, A., 3331
Hipfner, D. R., 3307
Hu, R.-H., 3265
Huang, D. P., 3225
Hubener, K., 3173
Hui, A. B. Y., 3225
Hyuga, S., 3366
Imai, Y., 3320
Ishikawa, T., 3320
Israel, M. A., 3192
Jacquemier, J., 3216
Janin, N., 3216
Johnson, T. E., 3257
Johnson-Thompson, M., 3380
Jones, D. C., 3168
Kainz, B., 3244
Kamb, A., 3199
Kantor, G. J., 3324
Keep, P. A., 3293
Kerangueven, F., 3216
Kleibeuker, J. H., 3270
Knuttila, S., 3320
Komiya, T., 3196
Korbelik, M., 3281
Kozaki, K.-i., 3366
Kristo, P., 3331
Krosl, G., 3281
Krosl, J., 3281
Kuroda, K., 3366
Lapre, J. A., 3270
Lawrence, T. S., 3203
Ledwith, B. J., 3257
Lee, J. C. K., 3225
Lee, W.-H., 3168
Leung, S.-F., 3225
Levi, D. S., 3192
Li, S., 3165
Liu, T., 3186
Liu, X.-L., 3371
Livingston, P. O., 3315
Lloyd, K. O., 3315
Lo, K.-W., 3225
Loney, T. L., 3203
Lupu, R., 3350
Manam, S., 3257
Mannick, E. E., 3238
Mantione, J., 3180
Margolis, B., 3165
Martin, B. A., 3244
Matsuyama, Y., 3366
McDaid, J., 3287
McManus, A., 3220
Melton, R. G., 3287
Meltzer, P. S., 3186
Mera, R., 3238
Miettinen, M., 3230
Miller, M. J. S., 3238
Monaco, C., 3173
Morriione, A., 3165
Nakajima, M., 3196
Nakatsuru, Y., 3320
Negrini, M., 3173
Nichols, W. W., 3257
Niculescu-Duvaz, I. A., 3287
Nishikawa, Y., 3366
Noguchi, T., 3216
Nojima, T., 3200
Oda, H., 3320
O'Hara, J. A., 3344
Ohta, M., 3173
Okawa, J., 3196
Olden, K., 3380
Ooi, J. Y. T., 3165
Oosterwijk, E., 3234
Pardi, R., 3211
Paulley, C. J., 3257
Pedley, R. B., 3293
Pegg, A. E., 3265
Perez, C., 3350
Peyrat, J.-P., 3216
Pinder, P. E., 3287
Pinkerton, R., 3220
Pritchard-Jones, K., 3220
Ragupathi, G., 3315
Ramachandran, N., 3180
Rao, G. N., 3338
Ray, D. W., 3276
Ray, M. E., 3186
Realpe, J. L., 3238
Ruiz, B., 3238
Saga, S., 3366
Salovaara, R., 3331
Sarlomo-Rikala, M., 3230
Schalken, J. A., 3234
Sehgal, I., 3359
Seidel, N. E., 3186
Shantz, L. M., 3265
Sharma, S. K., 3287
Shimazui, T., 3234
Shimizu, S., 3366
Shipley, J., 3220
Shizuta, Y., 3180
Sobol, H., 3216
Soderkvist, P., 3338
Springer, C. J., 3287
Stone, S., 3199
Stoppa-Lyonnet, D., 3216
Stride, B. D., 3307
Su, Y. A., 3186
Sullivan, C., 3380
Swartz, H. M., 3344
Takagi, S., 3366
Tang, C. K., 3350
Tekmal, R. K., 3180
Terton, D. S. M. L., 3270
Thompson, T. C., 3359
Toda, K., 3180
Tolbert, D. M., 3324
Toninelli, E., 3211
Trent, J. M., 3186
Valentinis, B., 3165
Van der Meer, R., 3270
Villa, A., 3211
Vonk, R. J., 3270
Vorechovsky, I., 3173
Wagner, L. K., 3257
Wabel, C., 3350
Watanabe, K., 3371
Wazer, D. E., 3371
Weber-Hall, S., 3220
White, A., 3276
Wiseman, R. W., 3338
Wright, A. F., 3287
Zarama, G., 3328
Zhang, S., 3315
Zhang, X.-J., 3238
Zhuang, S.-M., 3338
Zocchi, M. R., 3211

AUTHOR INDEX

July 15, 1996
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 11,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
5. substantially reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of over 11,000 member researchers in the cancer field;
10. the professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
12. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
13. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The seconder may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aol.com

RESPONSIBILITIES OF MEMBERSHIP

Candidates shall be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are $160, $95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ____________________________

LAST FIRST M.I. DATE OF BIRTH: __________

PRESENT POSITION/TITLE: ____________________________

INSTITUTIONAL AFFILIATION: ____________________________

INSTITUTIONAL ADDRESS: ____________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ____________________________ FAX NUMBER: ____________________________

E-MAIL NUMBER (CARRIER): ____________________________

PRINCIPAL FIELD OF RESEARCH (Please check only one):

Biochemistry and Biophysics  Biostatistics  Carcinogenesis
Cellular Biology and Genetics  Clinical Investigations  Endocrinology
Epidemiology  Immunology  Molecular Biology and Genetics
Preclinical Pharmacology and Experimental Therapeutics

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

CANDIDATE NOMINATED BY*: ____________________________

(Please print)

CANDIDATE SECONDED BY*: ____________________________

(Please print)

CANDIDATE IS APPLYING FOR (Check one):  □ ACTIVE  □ CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT
Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ____ years
Will the candidate make a long-term contribution to cancer research? _____Yes _____No
Does the candidate’s research adhere to accepted ethical standards? _____Yes _____No
I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* ____________________________ Date ____________________________

Signature of seconder* ____________________________ Date ____________________________

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AARC), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AARC enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AARC annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AARC also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. preferred access to the AARC Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AARC’s series of special conferences on timely subjects in the field;
7. substantially reduced registration rates at special conferences;
8. the receipt of AARC newsletters, meeting announcements, and an up-to-date Membership Directory;
9. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
10. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AARC. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Associate Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AARC, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $35 or $45 dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aol.com

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AARC Board of Directors. Dues for 1995 and 1996 have been set at $35 per year for residents of the Americas and $45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AARC who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AARC will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

<table>
<thead>
<tr>
<th>MacWrite</th>
<th>Microsoft Word (DOS, Windows, and Macintosh)</th>
<th>WordPerfect (DOS, Windows, and Macintosh)</th>
<th>XyWrite (DOS and Windows)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ability</td>
<td>Mass 11</td>
<td>SoloWriter</td>
<td></td>
</tr>
<tr>
<td>AmiPro</td>
<td>MS Windows Write</td>
<td>Sprint</td>
<td></td>
</tr>
<tr>
<td>A_{\text{s-tex}}</td>
<td>MS Works</td>
<td>Stx</td>
<td></td>
</tr>
<tr>
<td>Appleworks</td>
<td>MS Works WP Mac</td>
<td>SunWrite</td>
<td></td>
</tr>
<tr>
<td>ArborTeX</td>
<td>Multimate</td>
<td>Symphony</td>
<td></td>
</tr>
<tr>
<td>ArborText</td>
<td>Multimate Advantage</td>
<td>TEX</td>
<td></td>
</tr>
<tr>
<td>ClarisWorks WP</td>
<td>Nibia</td>
<td>TeX78</td>
<td></td>
</tr>
<tr>
<td>CPT 8000</td>
<td>Nisus (to ASCII file)</td>
<td>Text EExecutive</td>
<td></td>
</tr>
<tr>
<td>CTOS</td>
<td>Notewrite</td>
<td>Textures</td>
<td></td>
</tr>
<tr>
<td>Diablo</td>
<td>Obun</td>
<td>Total Word</td>
<td></td>
</tr>
<tr>
<td>DisplayWrite</td>
<td>OfficeWriter</td>
<td>Troff</td>
<td></td>
</tr>
<tr>
<td>Duet</td>
<td>PC Write</td>
<td>\mu TeX</td>
<td></td>
</tr>
<tr>
<td>Einstein</td>
<td>PFS First Choice</td>
<td>Volkswriter</td>
<td></td>
</tr>
<tr>
<td>Enable</td>
<td>Professional Write</td>
<td>VuWriter</td>
<td></td>
</tr>
<tr>
<td>EXP</td>
<td>Q&amp;A Write</td>
<td>Wang OiS</td>
<td></td>
</tr>
<tr>
<td>Final Word</td>
<td>Quark XPress</td>
<td>Wang WPS</td>
<td></td>
</tr>
<tr>
<td>FullWrite</td>
<td>RagTime MS Works</td>
<td>Wang Writer</td>
<td></td>
</tr>
<tr>
<td>GemWord Plus</td>
<td>(to ASCII file)</td>
<td>Window Works</td>
<td></td>
</tr>
<tr>
<td>IBM Writing Assistant</td>
<td>Rich Text Format</td>
<td>Windows Write</td>
<td></td>
</tr>
<tr>
<td>Interleaf</td>
<td>RSG (to ASCII file)</td>
<td>WiziWord</td>
<td></td>
</tr>
<tr>
<td>\LaTeX</td>
<td>Signature</td>
<td>Wordstar</td>
<td></td>
</tr>
<tr>
<td>Latex</td>
<td>\textsc{slite}X</td>
<td>Wordstar 2000</td>
<td></td>
</tr>
<tr>
<td>Leading Edge</td>
<td>SmartWhere</td>
<td>WriteNow</td>
<td></td>
</tr>
<tr>
<td>Lotus Manuscript</td>
<td>SmartWrite II</td>
<td>Xerox</td>
<td></td>
</tr>
<tr>
<td>Lotus Write</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Software packages that we are unable to translate:

<table>
<thead>
<tr>
<th>FrameMaker</th>
<th>Ready, Set, Go</th>
</tr>
</thead>
<tbody>
<tr>
<td>PageMaker</td>
<td>Scientific Writer</td>
</tr>
</tbody>
</table>

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

**PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.**
Albert Einstein Cancer Center
Tumor Cell Progression and Metastasis

The Albert Einstein Cancer Center, one of the first NCI-funded matrix centers in the US, along with the School of Medicine, has initiated a major expansion with new facilities and resources focused on basic and translational research programs. An investigator is sought to lead research activities focused on tumor progression and metastasis within the context of research activities in the areas of membrane biology, cytoskeleton and cell motility. The candidate will be appointed to a relevant basic science department and will join in a well-established interdisciplinary program in either immunology, virology, developmental biology, molecular genetics, membrane biology or drug development. A strong clinical oncology program offers the opportunity to extrapolate basic research findings into the clinic.

The Albert Einstein College of Medicine is located in a suburban neighborhood in New York City minutes from Westchester county, and provides a highly interactive research environment. Strong supporting core facilities include among others, transgenic and gene targeting facilities, structural biology, cytogenetics, DNA and protein chemistry and digital image capabilities. Competitive salaries and start up packages are provided. Please send curriculum vitae and three letters of reference to: Dr. Jeffrey Pollard, Chair, Recruitment Committee, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, Cancer Center, Belfer 1002, 1300 Morris Park Avenue, New York, NY 10461. Equal Opportunity Employer.

INTERNATIONAL CONFERENCE ON
GLUTATHIONE AND GLUTATHIONE-LINKED ENZYMES IN
HUMAN CANCER AND OTHER DISEASES

BIOLOGY, DIAGNOSIS, THERAPY AND PREVENTION

October 31-November 3, 1996 at Hilton Head Island Resort, South Carolina, USA

Conference Chair: Francis All-Osman; Co-Chairs: Ken Tew, Henry Friedman, Richard Strange

Scope and Aims: Recent research advances on the role of glutathione, glutathione-S-transferases and other GSH-linked proteins in normal cellular functions and pathologic processes are providing novel concepts for improved diagnosis, therapy, risk assessment and prevention of human cancer and other diseases. These findings are leading to novel therapeutic agents and strategies for the diagnosis, prognosis and therapy of cancer and other diseases, and for the monitoring of normal tissue injury. This conference will focus on recent developments in this field. The scientific sessions will cover a variety of topics, including cell and molecular biology, gene regulation, drug and radiation resistance, toxicology and drug metabolism, pathology, drug development, epidemiology and prevention, and clinical trials. Current knowledge in this rapidly evolving field will be shared and challenges for future focus in both basic and translational research discussed.


FOR FURTHER INFORMATION AND REGISTRATION CONTACT: Patricia Richter, Department of Experimental Pediatrics, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Tel. (713) 792-3495; FAX: (713) 794-5514; E-Mail: All-Osman@utmdacc.mda.uth.tmc.edu

We acknowledge the generous support of
Novel Approaches in Blood and Marrow Transplantation

October 2-6, 1996
Hotel del Coronado
San Diego, CA

CONFERENCE CO-CHAIRPERSONS
Bruce R. Blazar / Minneapolis, MN  O. Michael Colvin / Durham, NC

PROGRAM COMMITTEE
Karen S. H. Antman / New York, NY
Joseph R. Bertino / New York, NY
Barbara E. Bierer / Boston, MA
Richard E. Champlin / Houston, TX
Nelson J. Chao / Stanford, CA
Connie J. Eaves / Vancouver, BC, Canada
Olivera J. Finn / Pittsburgh, PA
Ronald E. Gress / Bethesda, MD
Helen E. Heslop / Memphis, TN
John H. Kersey / Minneapolis, MN
Keith M. Sullivan / Seattle, WA

PLENARY SESSIONS
Pharmacologic Approaches to Reducing Malignancy
Joseph R. Bertino / New York, NY
Robert B. Dissaio / Birmingham, AL
William Hryniuk / San Diego, CA
O. Michael Colvin / Durham, NC

Biologic Approaches to Reducing Malignancy
Martin Keat / Chicago, IL
Faith M. Uckun / Minneapolis, MN
John R. Murphy / Boston, MA
Glenn Dranoff / Boston, MA

Options for Hematopoietic Progenitor Cell Sources
Christopher Juttner / Palo Alto, CA
Peter M. Lansdorp / Vancouver, BC, Canada
Jan Noita / Los Angeles, CA
Paul Martin / Seattle, WA

Allogeneic Approaches to Reducing Malignancy Post-BMT
Bruce R. Blazar / Minneapolis, MN
Ronald E. Gress / Bethesda, MD
Robert Kormgold / Philadelphia, PA
Lee M. Nadler / Boston, MA

Biology of Breast Cancer
William P. Peters / Detroit, MI
Karen S. H. Antman / New York, NY
Jeffrey T. Holt / Nashville, TN
Daniel D. Von Hoff / San Antonio, TX

Growth Factors and Sources of Stem Cells
Joanne Kurtzberg / Durham, NC
Malcolm A. S. Moore / New York, NY

Graft Rejection/GVHD/GVL
Elie Gaulmy / Leiden, The Netherlands
Martin A. Cheever / Seattle, WA

Supportive Care
John R. Wingard / Atlanta, GA
Raleigh Bowden / Seattle, WA

Leukemias
Edward D. Ball / Pittsburgh, PA
Michael L. Cleary / Stanford, CA

Non-malignant Disorders: Congenital and Acquired
Robertson M. Parkman / Los Angeles, CA
Rainer F. Storb / Seattle, WA

Abstract Deadline: July 15, 1996

Information and Registration Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 / 215-440-9313 (FAX)
e-mail: aacr@aol.com